PamDx
Wolvenhoek 10, 's-Hertogenbosch, Noord-Brabant, 5200 BJ, The Netherlands
Overview
PamDx develops the IOPener® blood-test platform that rapidly measures protein kinases in cancer patients to support immunotherapy decision-making. The company is advancing clinical programs and preparing for commercialization of the IOPener platform. PamDx recently completed a €13 million Series A financing to fund those efforts. The company operates from an office in Den Bosch and employs over 30 people. Leadership includes chairman Jan van der Hoeven and CEO John Groten, and Helena Bond will act as an observer representing EISMEA. The organization recently rebranded from PamChip to PamDx as part of this next growth phase.
- Total raised
- $15M
- Funding rounds
- 1
- Latest round
- Series A
- Latest activity
- Apr 2026
Industries
- Biopharma
- Clinical Trials
- Health Care
- Medical Device
- Precision Medicine
Recent funding
Series A
Apr 2026
$15M
Team
No current team members are available.